Thursday, December 18, 2025
Moving the Covid Vaccine Goalposts
The Covid propagation and vaccine news is not pointing to happy outcomes
Wall Street Journal Fingers Columbia as Leader in Grad Students Whose Student Debt Leaves Them ‘Financially Hobbled for Life’
Columbia stands out in what a bad deal its graduate arts programs are. And President Bollinger is either clueless or indifferent.
The Future of Alzheimer’s Pharmaceutical Aducanumab – as a Medicine and as a Financial Product – What Happens Now?
The more you look at aducanumab, both the dubious FDA approval and the thin odds that it will perform medically, the less there is to like.
2:00PM Water Cooler 7/8/2021
~ Today’s Water Cooler ~
War on Science Persists Within Biden EPA as Staffers Allege Chemical Reports Altered
Whistleblowers charge that Trump-style doctoring of scientific reports is continuing under Biden.
How Intel Financialized and Lost Leadership in Semiconductor Fabrication
Intel is the poster child of how stock buybacks come at the cost of technological innovation.
The Real Reason OPEC Talks Broke Down
OPEC is squabbling again. Will the factions settle their hash?
Buyers’ Strike? Mortgage Applications Drop 8% Below 2019, as Home Buyers Get Second Thoughts about “Raging Mania”
Falling mortgage applications and rising home inventories signal a coming housing market pullback.
2:00PM Water Cooler 7/7/2021
Patient readers, sorry to be a bit late; I got caught up in the Nikole Hannah-Jones saga,
Far More Adults Don’t Want Children Than Previously Thought
Probling why more people arent interested in having children.
A Quick Comment on China Stomping on Chinese Stock Listings in the US
Another big and costly dustup over Chinese listings in the US. But now Chinese officials signal they want broad-scale change.
Aducanumab Approval, Part 2: Dirty Drug Dealings
Yves here. We’re doing a bit of catchup by featuring some significant stories that were still crowded out a bit due to the competing news plus the Fourth of July tuneout. One is on the super dodgy approval of the big ticket, very dubious effectiveness Alzheimer’s drug Aducanumab. And “big ticket” is no understatement; the […]
